Diagnostic Efficacy of Natriuretic Peptide: NT-ProBNP in Hemodialysis Patients with Left Ventricular Failure

Year 2024, , 135 - 142, 29.06.2024

Şenol Tayyar , Bayram Ali Uysal

https://doi.org/10.17343/sdutfd.1332293

Abstract

Objective: In the general population, plasma concentrations of natriuretic peptides such as brain natriuretic peptide (BNP), are useful markers to predict left ventricular hypertrophy and left ventricular (LV) systolic dysfunction. Left ventricular hypertrophy in dialysis patients is exceedingly frequent and predicts mortality in these patients. LV systolic dysfunction is also frequent due to high coronary artery disease (CAD) prevalence in this population. The present study aimed to evaluate the clinical diagnostic potential of N-terminal pro-brain natriuretic peptide (NT-proBNP); as an indicator for left ventricular (LV) systolic dysfunction and left ventricular mass (LVM), in chronic hemodialysis patients.
Material and Method: 76 patients with end-stage renal disease (54 males and 22 females, mean age 60.51±13.96 years) who had been on regular hemodialysis treatment twice or three times a week were enrolled in this study. Patients were divided into two groups based on left ventricular ejection fraction (LVEF). Left ventricular systolic dysfunction was defined as LVEF ≤40%. Basic biochemical parameters, NT-proBNP, and echocardiographic parameters including left ventricular mass (LVM) and left ventricular mass index (LVMI) were measured.
Results: Mean concentration of serum NT-proBNP was 8333 (208-35000) pg/ml, and this parameter was not significantly different between the two groups (13136 (361-35000) pg/ml vs. 6617 (20-33805) pg/ml, p:0.16). Multivariate analysis results of logarithmic transformed NT-proBNP showed correlation only with RVEF. The left ventricular end-systolic diameter was significantly lower in the normal LV systolic function group (35.4±8.2 vs. 31.3±7.1 mm, p:0.04).
Conclusion: Our findings suggest that NT-proBNP is inadequate to determine LV systolic dysfunction in chronic hemodialysis patients.

Keywords

Hemodialysis, NT-proBNP, left ventricular systolic dysfunction

Project Number

Yok

SOL VENTRİKÜL YETMEZLİĞİ OLAN HEMODİYALİZ HASTALARINDA BİR NATRİÜRETİK PEPTİT OLAN NT-ProBNP’NİN TANISAL DEĞERİ

Abstract

Amaç: Sağlıklı popülasyonda, atriyal ve beyin natriüretik peptit (ANP ve BNP) gibi natriüretik peptitlerin plazma seviyeleri, sol ventrikül (LV) hipertrofisini ve LV yetmezliğini tahmin etmek için yararlı belirteçlerdir. Kronik böbrek yetersizliğinde (KBY) LVH son derece sıktır ve bu hastalarda mortaliteyi öngördürür. Bu popülasyonda yüksek koroner arter hastalığı (KAH) prevalansı nedeniyle LV yetmezliği de sıktır. Çalışmamızın amacı; son evre KBY hastalarında LV yetmezliği ve sol ventrikül kütlesi (LVM) için bir gösterge olarak, N-terminal pro-beyin natriüretik peptidin (NT-proBNP) teşhis potansiyelini belirlemektir.
Gereç ve Yöntemler: Çalışmaya son evre böbrek yetersizliği olan ve haftada iki veya üç kez düzenli hemodiyaliz yapılan 76 hasta (54 erkek ve 22 kadın, ortalama yaş 60.51±13.96 yıl) alındı. Hastalar LV ejeksiyon fraksiyonuna (LVEF) göre iki gruba ayrıldı. LV sistolik disfonksiyonu, LVEF ≤%40 olarak kabul edildi. Temel biyokimyasal parametreler, NT-proBNP, LVM ve sol ventrikül kütle indeksi (LVMI) dahil olmak üzere ekokardiyografik parametreler ölçüldü.
Bulgular: Ortalama serum NT-proBNP konsantrasyonu 8333 (208-35000) pg/ml idi ve bu parametre iki grup arasında anlamlı farklılık göstermedi [13136 (361-35000) pg/ml'ye karşılık 6617 (20-33805) pg/ml, p: 0.16]. Logaritmik olarak dönüştürülmüş NT-proBNP çok değişkenli analiz sonuçlarında sadece LVEF ile korelasyon göstermiştir. Sol ventrikül sistol sonu çapı normal LV fonksiyonu olan grupta anlamlı olarak daha düşüktür (35.4±8.2'ye karşı 31.3±7.1 mm, p: 0.04).
Sonuç: Bulgularımız, NT-proBNP'nin diyaliz tedavisi alan KBY'li hastalarda sol ventrikül yetmezliğini saptamada yetersiz olduğunu düşündürmektedir.

Keywords

Hemodiyaliz, NT-proBNP, sol ventrikül yetmezliği

Supporting Institution

Yok

Project Number

Yok

Thanks

Desteğiniz için şimdiden teşekkürler ve saygılarımı sunarım.

References

• 1. Yasue H, Yoshimura M, Sumida H, Kituta K, et al. Localization and Mechanism of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart Failure. Circulation 1994;90(1):195-203.
• 2. Mukoyama M, Nakao K, Hosoda K, Suga S, et al. Brain Natriuretic Peptide as a Novel Cardiac Hormone in Humans. Evidence for an Exquisite Dual Natriuretic Peptide System, Atrial Natriuretic Peptide, and Brain Natriuretic Peptide. J Clin Invest 1991;87(4):1402-12.
• 3. Kohno M, Horio T, Yokokaw K, Murakawa K, et al. Brain Natriuretic Peptide as a Cardiac Hormone in Essential Hypertension. Am J Med 1992;92(1):29-34.
• 4. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The Amino-Terminal Portion of Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma. Biochem Biophys Res Commun 1995;214(3):1175-83.
• 5. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvulotion Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload. Hypertension 2000;36(3):355-9.
• 6. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of Brain Natriuretic Peptide (BNP) in Human Plasma: Evidence for High Molecular Weight BNP as a Major Plasma Component in Heart Failure. J Clin Endocrinol Metab 1993;76(4):832-8.
• 7. Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic Potential of Cardiac Natriuretic Peptides in Dialysis Patients. Kidney Int 2001;59(4):1559-66.
• 8. Wang AY, Lam CW, Yu CM, Chan IH, et al. N-Terminal Pro-Brain Natriuretic Peptide: An İndependent Risk Predictor of Cardiovascular Congestion, Mortality, and Adverse Cardiovascular Outcomes in Chronic Peritoneal Dialysis Patients. J Am Soc Nephrol 2007;18(1):321-30.
• 9. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, et al. Cardiac Natriuretic Peptides are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. J Am Soc Nephrol 2001;12(7):1508-15.
• 10. Foley RN, Parfrey PS, Harnett JD, Kent GM, et al. The Prognostic İmportance of Left Ventricular Geometry in Uremic Cardiomyopathy. J Am Soc Nephrol 1995;5(12):2024-31.
• 11. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements. Circulation 1978;58(6):1072-83.
• 12. Schiller NB, Shah PM, Crawford M, DeMaria A, et al. Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2(5):358-67.
• 13. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of Obesity and Gender to Left Ventricular Hypertrophy in Normotensive and Hypertensive Adults. Hypertension 1994;23(5):600-6.
• 14. Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and Reproducibility of Biplane Two-Dimensional Echocardiographic Measurements of Left Ventricular Dimensions and Function. Eur Heart J 1997;18(3):507-13.
• 15. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al., Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med, 2002;347(3):161-7.
• 16. Mueller C, Scholar A, Laule-Kilian K, Martina B, et al. Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. N Engl J Med 2004;350(7):647-54.
• 17. Davis M, Espiner M, Richards G, Billing J, Town I, et al. Plasma Brain Natriuretic Peptide in Assessment of Acute Dyspnoea. Lancet 1994;343(8895):440-4.
• 18. Berger R, Huelsman M, Strecker K, Bojic A, et al. B-Type Natriuretic Peptide Predicts Sudden Death in Patients with Chronic Heart Failure. Circulation 2002;105(20):2392-7.
• 19. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A Pilot Study. J Am Coll Cardiol 2001;37(2):386-91.
• 20. Koglin J, Pehlivanlı S, Schwaiblmair M, Voseger M, et al. Role of Brain Natriuretic Peptide in Risk Stratification of Patients with Congestive Heart Failure. J Am Coll Cardiol 2001;38(2):1934-41.
• 21. Yu CM, Sanderson JE. Plasma Brain Natriuretic Peptide--An İndependent Predictor of Cardiovascular Mortality in Acute Heart Failure. Eur J Heart Fail 1999;1(1):59-65.
• 22. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a Rapid B-Natriuretic Peptide Assay in Differentiating Congestive Heart Failure from Lung Disease in Patients Presenting with Dyspnea. J Am Coll Cardiol 2002;39(2):202-9.
• 23. Cowie MR, Struthers AD, Wood DA, Coats AJ, et al. Value of Natriuretic Peptides in Assessment of Patients with Possible New Heart Failure in Primary Care. Lancet 1997;350(9088):1349-53.
• 24. Parfrey PS, Harnett JD, Barre PE. The Natural History of Myocardial Disease in Dialysis Patients. J Am Soc Nephrol 1991;2(1):2-12.
• 25. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and Risk Factors for Left Ventricular Disorders in Chronic Uraemia. Nephrol Dial Transplant 1996;11(7):1277-85.
• 26. London GM, Guerin AP, Marchais SJ. Pathophysiology of Left Ventricular Hypertrophy in Dialysis Patients. Blood Purif 1994;12(4-5):277-83.
• 27. Kohno M, Horio T, Yokokawa K, Yasunari K, et al. Brain Natriuretic Peptide as a Marker for Hypertensive Left Ventricular Hypertrophy: Changes During 1-Year Antihypertensive Therapy with Angiotensin-Converting Enzyme Inhibitor. Am J Med 1995;98(3):257-65.
• 28. Yamomoto K, Burnett JCJr, Jougasaki M, Nishimura RA, et al. Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular Hypertrophy. Hypertension 1996;28(6):988-94.
• 29. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, et al. Relationship Between Left Ventricular Geometry and Natriuretic Peptide Levels in Essential Hypertension. Hypertension 1996;28(1):22-30.
• 30. Muschol MW, Schunkert H, Muders F, et al. Neurohormonal Activity and Left Ventricular Geometry in Patients with Essential Arterial Hypertension. Am Heart J 1998;135(1):58-66.
• 31. Schirmer H, Omland T. Circulating N-Terminal Pro-Atrial Natriuretic Peptide is an Independent Predictor of Left Ventricular Hypertrophy in the General Population. The Tromso Study. Eur Heart J 1999;20(10):755-63.
• 32. Daniels LB, Maisel AS. Natriuretic Peptides. J Am Coll Cardiol 2007;50(25):2357-68.
• 33. Kim WCW, Kim WY, Lim KS, Park YK. B-Natriuretic Peptide (BNP) Assay for Diagnosis of Congestive Heart Failure. J Korean Soc Emerg Med 2003;14:624-9.
• 34. Goto T, Takase H, Toriyama T, Sugiure T, et al. Increased Circulating Levels of Natriuretic Peptides Predict Future Cardiac Event in Patients with Chronic Hemodialysis. Nephron 2002;92(3):610-5.
• 35. Nitta K, Kawashima A, Yumura W, Naruse M, et al. Plasma Concentration of Brain Natriuretic Peptide as an İndicator of Cardiac Ventricular Function in Patients on Hemodialysis. Am J Nephrol 1998;18(5):411-5.
• 36. David S, Kümpers P, Seidler V, Biertz F, et al. Diagnostic Value of N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) for Left Ventricular Dysfunction in Patients with Chronic Kidney Disease Stage 5 on Haemodialysis. Nephrol Dial Transplant 2008;23(4):1370-7